CPC Advisors LLC Buys New Holdings in Stryker Corporation $SYK

CPC Advisors LLC bought a new stake in Stryker Corporation (NYSE:SYK) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,531 shares of the medical technology company’s stock, valued at approximately $890,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Czech National Bank raised its holdings in Stryker by 3.9% in the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after acquiring an additional 3,366 shares in the last quarter. Davis R M Inc. increased its stake in Stryker by 1.8% in the third quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after purchasing an additional 2,512 shares during the last quarter. Terra Alpha Investments LLC purchased a new position in Stryker in the third quarter valued at approximately $1,216,000. Kepler Cheuvreux Suisse SA purchased a new position in Stryker in the third quarter valued at approximately $27,952,000. Finally, Diversified Trust Co increased its stake in Stryker by 45.6% in the third quarter. Diversified Trust Co now owns 12,445 shares of the medical technology company’s stock valued at $4,601,000 after purchasing an additional 3,899 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $329.63 on Thursday. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The firm has a market cap of $126.24 billion, a PE ratio of 39.24, a price-to-earnings-growth ratio of 1.91 and a beta of 0.92. The company’s 50 day simple moving average is $351.26 and its 200-day simple moving average is $358.80. Stryker Corporation has a 12-month low of $319.32 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. The business had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the firm posted $4.01 earnings per share. As a group, equities analysts predict that Stryker Corporation will post 14.92 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 41.90%.

Wall Street Analyst Weigh In

Several equities analysts have commented on SYK shares. Truist Financial dropped their price target on shares of Stryker from $395.00 to $380.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. William Blair reiterated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Robert W. Baird set a $437.00 price target on shares of Stryker in a research note on Friday, January 30th. Citigroup dropped their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $465.00 price target on shares of Stryker in a research note on Wednesday, March 4th. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $421.11.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.